ESC Heart Failure 2024

Introduction

ESC Heart Failure 2024 is the premier international scientific congress dedicated entirely to heart failure medicine, organized by the Heart Failure Association of the European Society of Cardiology under the umbrella of European Society of Cardiology.

Held from May 11–14, 2024 in Lisbon and online, the congress delivered a comprehensive review of contemporary heart failure science, prevention strategies, diagnostic advances, pharmacologic therapies, device management, acute heart failure care, and multidisciplinary treatment approaches.

Recognized as the world’s leading congress focused exclusively on heart failure, ESC Heart Failure 2024 featured global faculty experts, interactive case discussions, late-breaking science presentations, clinical “How-To” sessions, translational research, and guideline-driven educational content spanning the entire spectrum of heart failure care.

The congress emphasized both evidence-based clinical practice and emerging innovations shaping the future of cardiovascular medicine and heart failure management.

Congress Overview

ESC Heart Failure 2024 brought together clinicians, researchers, allied professionals, and trainees from around the world to review advances in:

• Heart failure prevention
• Acute and chronic heart failure management
• Heart failure with reduced ejection fraction (HFrEF)
• Heart failure with preserved ejection fraction (HFpEF)
• Cardiomyopathies
• Device therapy and advanced heart failure
• Pulmonary hypertension and right heart failure
• Mechanical circulatory support
• Precision medicine and biomarkers
• Late-breaking clinical trials and registries

The meeting included more than 80 scientific sessions featuring world-renowned faculty, multidisciplinary collaboration, interactive clinical cases, and dedicated educational sessions for both established clinicians and younger heart failure specialists.

Why This Congress Is Important

Heart failure remains one of the leading causes of morbidity, hospitalization, and mortality worldwide. Rapid advances in pharmacotherapy, device therapy, biomarker interpretation, precision imaging, and multidisciplinary management have significantly transformed the treatment landscape in recent years.

Modern heart failure management now includes:

• Quadruple guideline-directed medical therapy (GDMT)
• SGLT2 inhibitors across the HF spectrum
• Novel cardiomyopathy therapies
• Advanced mechanical circulatory support
• Structural heart interventions
• Remote monitoring and digital health technologies
• Precision phenotyping and biomarker-guided treatment

ESC Heart Failure 2024 addressed these rapidly evolving developments through evidence-based scientific discussions, late-breaking clinical trial analysis, and practical educational sessions designed to improve patient outcomes and clinical implementation.

What Participants Learned

Participants attending ESC Heart Failure 2024 strengthened their expertise in comprehensive heart failure care.

Learning objectives included:

• Applying updated ESC and international heart failure guidelines
• Managing acute and chronic heart failure syndromes
• Understanding contemporary HF pharmacologic therapies
• Interpreting late-breaking heart failure trial data
• Optimizing GDMT implementation strategies
• Evaluating advanced heart failure therapies and devices
• Managing cardiomyopathies and complex HF phenotypes
• Applying multimodality imaging in heart failure care
• Integrating remote monitoring and digital cardiology tools
• Improving multidisciplinary and network-based HF management

The congress integrated preventive cardiology, acute care, advanced heart failure, device therapy, imaging, and translational science into a comprehensive educational platform.

Core Topics & Educational Areas

Heart Failure Pharmacotherapy

Guideline-Directed Medical Therapy (GDMT)

SGLT2 Inhibitors

ARNI Therapy

Mineralocorticoid Receptor Antagonists

Emerging HF Medications

Acute Heart Failure

Acute Decompensated Heart Failure

Cardiogenic Shock

Diuretic Strategies

ICU & Advanced Care Management

HFpEF & HFrEF

Heart Failure with Preserved EF

Heart Failure with Reduced EF

Mid-Range & Phenotype-Specific HF

Personalized HF Therapy

Cardiomyopathies

Dilated Cardiomyopathy

Hypertrophic Cardiomyopathy

Amyloidosis

Inflammatory & Genetic Cardiomyopathies

Advanced Heart Failure

Mechanical Circulatory Support

LVAD Therapy

Heart Transplantation

Palliative & End-Stage HF Care

Imaging & Diagnostics

Echocardiography in HF

Cardiac MRI

Biomarkers & Risk Stratification

Hemodynamic Monitoring

Arrhythmias & Devices

ICD & CRT Therapy

Conduction System Pacing

Atrial Fibrillation in HF

Device Optimization

Pulmonary Hypertension & Right Heart Failure

Pulmonary Vascular Disease

Right Ventricular Dysfunction

Advanced Hemodynamic Assessment

Clinical Cases & Interactive Sessions

How-To Sessions

Case-Based Heart Failure Management

Interactive Clinical Discussions

Multidisciplinary Team Approaches

Late-Breaking Science

Landmark Clinical Trials

Registry Data

Emerging Therapeutics

Translational Cardiovascular Research

Educational Experience & Learning Features

ESC Heart Failure 2024 combined scientific innovation with practical clinical heart failure education.

Educational features included:

• More than 80 scientific sessions
• Late-breaking clinical trial presentations
• Interactive clinical case discussions
• “How-To” practical educational sessions
• World-renowned heart failure faculty
• Multidisciplinary cardiovascular collaboration
• Research Gateway scientific presentations
• Young community and career development sessions
• Hybrid in-person and online access
• Comprehensive ESC heart failure curriculum

The congress integrated translational research, preventive cardiology, advanced therapeutics, imaging, device therapy, and acute care medicine into a world-class educational experience.

Who Should Attend

ESC Heart Failure 2024 was designed for healthcare professionals involved in cardiovascular and heart failure care.

This congress was especially valuable for:

• Cardiologists
• Heart failure specialists
• Internal medicine physicians
• Electrophysiologists
• Intensivists and critical care physicians
• Cardiovascular researchers
• Advanced practice providers
• Heart failure nurses
• Fellows and trainees in cardiology
• Allied cardiovascular healthcare professionals

The curriculum was particularly relevant for clinicians seeking advanced updates in heart failure diagnosis, therapeutics, and multidisciplinary care.

Clinical Applications & Practice Benefits

ESC Heart Failure 2024 provided clinically practical education focused on improving outcomes in patients with heart failure.

Participants gained practical insight into:

• Modern implementation of HF guideline therapies
• Acute heart failure stabilization strategies
• Advanced heart failure referral pathways
• Device-based therapy optimization
• Cardiomyopathy diagnosis and treatment
• Precision medicine and biomarker integration
• Heart failure imaging interpretation
• Multidisciplinary heart failure programs
• Late-breaking clinical trial application
• Evidence-based cardiovascular risk reduction

The educational content strengthened both scientific understanding and real-world heart failure clinical management.

Professional Summary

ESC Heart Failure 2024 from the Heart Failure Association of the European Society of Cardiology and European Society of Cardiology represented the world’s leading scientific meeting dedicated exclusively to heart failure medicine.

Held in Lisbon and online, the congress delivered comprehensive education on acute and chronic heart failure, HFpEF, cardiomyopathies, advanced therapies, device management, imaging, biomarkers, and late-breaking cardiovascular science.

Its combination of global faculty expertise, guideline-focused teaching, interactive clinical education, translational science, and practice-changing clinical trial updates made ESC Heart Failure 2024 an essential educational event for cardiologists, heart failure specialists, and cardiovascular clinicians worldwide.